Efficacy and safety of recombinant Bifidobacterium breve carrying HPV16 E7 shRNA and IL-12 gene against mouse cervical cancer xenografts

DELIZAER· n Rehema; KADIRYA· Kaysar; WANG Zhongxiang; LIU Dan; LI Yijie.
Chinese Journal of Cancer Biotherapy ; (6): 301-307, 2022.
Artículo en Zh | WPRIM | ID: wpr-924661

Documentos relacionados

  1. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
  2. Cholesterol Conjugates of Small Interfering RNA: Linkers and Patterns of Modification.
  3. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo.
  4. Core Role of Hydrophobic Core of Polymeric Nanomicelle in Endosomal Escape of siRNA.
  5. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery.
  6. B cell-specific mAb-siRNA conjugates improve experimental myasthenia.
  7. Shorter Is Better: The α-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs.
  8. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury.
  9. The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy.
  10. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo.